<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Testosterone treatment of male hypogonadism</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Testosterone treatment of male hypogonadism</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Testosterone treatment of male hypogonadism</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter J Snyder, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alvin M Matsumoto, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathryn A Martin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 21, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Hypogonadism in a male refers to a decrease in either of the two major functions of the testes: sperm production or <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> production. These abnormalities can result from disease of the testes (primary hypogonadism) or disease of the pituitary or hypothalamus (secondary hypogonadism). The use of testosterone to treat hypogonadism in adult men, primary or secondary, is reviewed here. The clinical manifestations and diagnosis of male hypogonadism, induction of spermatogenesis in men with secondary hypogonadism, and induction of puberty with testosterone are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7462.html" rel="external">"Clinical features and diagnosis of male hypogonadism"</a> and  <a class="medical medical_review" href="/z/d/html/7463.html" rel="external">"Induction of fertility in males with secondary hypogonadism"</a> and  <a class="medical medical_review" href="/z/d/html/5814.html" rel="external">"Approach to the patient with delayed puberty", section on 'Testosterone therapy'</a>.)</p><p class="headingAnchor" id="H165681337"><span class="h1">MECHANISMS OF TESTOSTERONE ACTION</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">Testosterone</a> has many different biologic effects, at least in part because it can act as three hormones. It can act directly by binding to the androgen receptor. It can also act in tissues that express the enzyme 5-alpha-reductase, via conversion to dihydrotestosterone, which binds more avidly to the androgen receptor than testosterone itself. Finally, it can act as an estrogen following conversion by aromatase to estradiol, which binds to the estrogen receptor.</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">Testosterone</a> requires conversion to dihydrotestosterone for its action on the external genitalia (which include the prostate gland) and sexual hair. This mechanism provides the basis for the use of the 5-alpha-reductase inhibitor, <a class="drug drug_general" data-topicid="8447" href="/z/d/drug information/8447.html" rel="external">finasteride</a>, to treat benign enlargement of the prostate and male pattern baldness. (See  <a class="medical medical_review" href="/z/d/html/3321.html" rel="external">"Male pattern hair loss (androgenetic alopecia in males): Management", section on 'Oral finasteride'</a> and  <a class="medical medical_review" href="/z/d/html/6891.html" rel="external">"Medical treatment of benign prostatic hyperplasia", section on '5-alpha reductase inhibitors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">Testosterone</a> requires conversion to estradiol for much of its action on bone. This effect is illustrated by the rare condition of aromatase deficiency in men, which results in failure of epiphyseal closure and severe osteoporosis. Treatment with estradiol corrects both. (See  <a class="medical medical_review" href="/z/d/html/2049.html" rel="external">"Etiology of osteoporosis in men"</a>.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">Testosterone</a> also appears to require conversion to estradiol to stimulate normal sexual function and decrease body fat in men, as shown by an experiment in which men 20 to 50 years old were treated with a gonadotropin-releasing hormone (GnRH) agonist to suppress testosterone and estradiol secretion and then replaced with testosterone, with or without an aromatase inhibitor [<a href="#rid1">1</a>]. Addition of the aromatase inhibitor partially blocked testosterone from increasing libido and erectile function and from decreasing subcutaneous and intraabdominal fat.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">Testosterone</a> does not appear to require conversion to estradiol to affect muscle. In the experiment above [<a href="#rid1">1</a>], treatment with the aromatase inhibitor did not block the effect of testosterone on lean muscle mass, thigh muscle area, or leg press strength.</p><p></p><p class="headingAnchor" id="H2"><span class="h1">GENERAL PRINCIPLES</span><span class="headingEndMark"> — </span>The following principles should guide <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> therapy:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">Testosterone</a> should be administered <strong>only to a man who is hypogonadal</strong>, as evidenced by clinical symptoms and signs consistent with androgen deficiency and a distinctly subnormal serum testosterone concentration. In comparison, increasing the serum testosterone concentration in a man who has symptoms suggestive of hypogonadism, but whose testosterone concentration is already normal, will not relieve those symptoms. (See  <a class="medical medical_review" href="/z/d/html/7462.html" rel="external">"Clinical features and diagnosis of male hypogonadism", section on 'Symptoms'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Symptoms and signs suggestive of androgen deficiency include low libido, decreased morning erections, loss of body hair, low bone mineral density, gynecomastia, and small testes. Symptoms and signs such as fatigue, depression, anemia, reduced muscle strength, and increased fat mass are less specific [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">Testosterone</a> can be replaced satisfactorily whether the testosterone deficiency is due to primary or secondary hypogonadism.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The principal goal of <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> therapy is to restore the serum testosterone concentration to the normal range. It is not yet known if restoring the normal circadian rhythm of testosterone is important. (See  <a class="medical medical_review" href="/z/d/html/7474.html" rel="external">"Male reproductive physiology"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The role of <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> replacement to treat the decline in serum testosterone concentration that occurs with increasing frequency in men above age 60 years, in the absence of identifiable pituitary or hypothalamic disease, is uncertain. (See  <a class="medical medical_review" href="/z/d/html/7457.html" rel="external">"Approach to older males with low testosterone"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">Testosterone</a> therapy is indicated only for testosterone deficiency, <strong>not</strong> for impaired spermatogenesis. Testosterone therapy impairs spermatogenesis further by suppressing pituitary gonadotropin secretion.</p><p></p><p class="headingAnchor" id="H3937930"><span class="h1">CLINICAL BENEFITS OF TESTOSTERONE THERAPY IN HYPOGONADAL MEN</span><span class="headingEndMark"> — </span>The desirable effects of <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> administration include the development or maintenance of secondary sexual characteristics and increases in libido, muscle strength, fat-free mass, and bone density. Undesirable effects related directly to testosterone include acne, prostate disorders (such as benign prostatic hyperplasia [BPH] symptoms), sleep apnea, and erythrocytosis. (See <a class="local">'Potential adverse effects'</a> below.)</p><p class="headingAnchor" id="H3937990"><span class="h2">Virilization/sexual function</span><span class="headingEndMark"> — </span>Normalization of the serum <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> concentration should lead to normal virilization in men who are not virilized and maintenance of virilization in those who already are. Men who become hypogonadal in adulthood and are still normally virilized, but whose hypogonadism is manifested by a decrease in libido and energy, should note a marked improvement in these symptoms. Failure of improvement when the serum testosterone concentration has been restored to normal suggests another cause of the symptoms.</p><p class="headingAnchor" id="H3937996"><span class="h2">Muscle strength/fat-free mass</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">Testosterone</a> replacement also leads to substantial improvements in muscle strength and fat-free mass in hypogonadal men. In one report, for example, the administration of 100 mg of testosterone enanthate once a week for 10 weeks to hypogonadal men increased their strength in the bench press by 22 percent, their squat strength by 45 percent, and fat-free mass by 5 percent [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H3938002"><span class="h2">Bone density</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">Testosterone</a> replacement improves bone density in male hypogonadism, as illustrated in a study of 72 such men receiving testosterone replacement therapy [<a href="#rid4">4</a>]. The increase in bone density averaged 39 percent in the first year of testosterone replacement, and it eventually reached and was maintained in the normal range. The response was greatest in the first year in previously untreated patients and was most pronounced in those with lowest bone density measurements at baseline. (See  <a class="medical medical_review" href="/z/d/html/2059.html" rel="external">"Treatment of osteoporosis in men", section on 'Congenital hypogonadism'</a>.)</p><p class="headingAnchor" id="H12676862"><span class="h2">Other possible effects</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">Testosterone</a> has also been postulated to improve mood and cognition, but these effects have not been demonstrated convincingly:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mood</strong> – Data on the impact of <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> therapy on mood are inconsistent. In men with moderately severe hypogonadism, treatment with long-acting testosterone esters for 30 weeks significantly improved several measures of mood compared with pretreatment, but the study was neither controlled nor blinded [<a href="#rid5">5</a>]. In young and old men made hypogonadal by a gonadotropin-releasing hormone (GnRH) analog, graded doses of testosterone enanthate did not improve two measures of mood [<a href="#rid6">6,7</a>]. In contrast, two small trials suggest a beneficial effect of testosterone on mood in older men with subclinical depression. (See  <a class="medical medical_review" href="/z/d/html/7457.html" rel="external">"Approach to older males with low testosterone", section on 'Testosterone therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cognition</strong> – In older men with slightly low <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> concentrations, administration of testosterone enanthate every two weeks did not significantly change any of several measures of cognition [<a href="#rid8">8</a>]. Other data in older men have not shown an effect of testosterone therapy on cognition. (See  <a class="medical medical_review" href="/z/d/html/7457.html" rel="external">"Approach to older males with low testosterone", section on 'Testosterone therapy'</a>.)</p><p></p><p class="headingAnchor" id="H165681670"><span class="h2">Time course of effects</span><span class="headingEndMark"> — </span>The time course of the effects of <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> replacement is variable. This was illustrated in a three-year study of physiologic transdermal testosterone replacement in 18 previously untreated hypogonadal men [<a href="#rid9">9</a>]. Increases in fat-free mass, prostate volume, erythropoiesis, energy, and sexual function occurred within the first three to six months. In contrast, the full effect on bone mineral density did not occur until 24 months.</p><p class="headingAnchor" id="H3937937"><span class="h1">GENERAL APPROACH TO TREATMENT</span></p><p class="headingAnchor" id="H863673345"><span class="h2">Appropriate candidates</span></p><p class="headingAnchor" id="H345439314"><span class="h3">Hypogonadal adult men</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">Testosterone</a> should be administered <strong>only to an adult male who is hypogonadal</strong>, as evidenced by clinical symptoms and signs consistent with androgen deficiency and a subnormal morning (8 to 10 AM) serum testosterone concentration on three separate occasions. Ideally, samples should be drawn fasting; in one report, an oral glucose load suppressed serum testosterone concentrations acutely [<a href="#rid10">10</a>]. Symptoms and signs suggestive of androgen deficiency include low libido, decreased morning erections, loss of body hair, low bone mineral density, gynecomastia, and small testes. Symptoms and signs such as fatigue, depression, anemia, reduced muscle strength, and increased fat mass are less specific. The beneficial effects of testosterone in these men are clear, and they should be treated with testosterone to raise their serum testosterone concentrations to normal.</p><p class="headingAnchor" id="H2684845042"><span class="h3">Older men with low testosterone and symptoms of hypogonadism</span><span class="headingEndMark"> — </span>The role of <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> replacement to treat the decline in serum testosterone concentration that occurs with aging in men, in the absence of identifiable pituitary or hypothalamic disease, has been unclear. However, results from the Testosterone Trials suggest that testosterone has a beneficial effect on sexual function, mood, possibly walking, bone density, and anemia [<a href="#rid11">11</a>]. Results of these trials are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/7457.html" rel="external">"Approach to older males with low testosterone"</a>.)</p><p class="headingAnchor" id="H863673533"><span class="h3">Inappropriate use of testosterone in healthy, middle-aged men</span><span class="headingEndMark"> — </span>There has been a dramatic increase in inappropriate use of <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> therapy in healthy, middle-aged and older men. It is important for clinicians to understand that the diagnosis of testosterone deficiency should be made <strong>only</strong> on the basis of clinical symptoms and signs consistent with androgen deficiency and consistently subnormal serum testosterone concentrations at 8 to 10 AM on three occasions.</p><p>For men with vague symptoms that could be the result of low <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> (eg, fatigue) and a single, but not repeatedly, subnormal serum testosterone concentration, we recommend strongly against testosterone use. The Endocrine Society's guidelines and others also strongly advocate this approach [<a href="#rid2">2,12</a>]. Treatment should not be prescribed on a "trial" basis, because the results are not interpretable and because once men have started treatment, they may find cessation difficult because of the prolonged period of hypogonadism during recovery of the pituitary-testicular axis. In addition, testosterone therapy eventually results in suppression of spermatogenesis and decreased testicular size. (See <a class="local">'Suppression of spermatogenesis'</a> below.)</p><p>The rise in <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> prescriptions in healthy, middle-aged men is likely due, at least in part, to direct-to-consumer advertising (DTCA) encouraging use of testosterone products for nonspecific symptoms, such as decreased energy and sexual interest [<a href="#rid13">13-16</a>]. In one study of 75 designated market areas with high rates of DTCA of specific testosterone products and/or testosterone deficiency ("low T"), approximately 1 million of 17 million men (6 percent) had themselves tested for low testosterone for the first time between 2009 and 2013 [<a href="#rid17">17</a>]. Approximately 280,000 men (1.6 percent) started testosterone therapy during that interval. The study authors calculated that each exposure to DTCA was associated with a 0.6, 0.7, or 0.8 percent increase in testosterone testing, initiation of therapy, or initiation of testosterone therapy without baseline testing, respectively. Although the percentage changes are small, in large populations, the impact is large.</p><p class="headingAnchor" id="H3938851"><span class="h2">Choice of testosterone regimen</span><span class="headingEndMark"> — </span>Choosing among the different <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> preparations requires an understanding of their pharmacokinetics. Native testosterone is absorbed well from the intestine, but it is metabolized so rapidly by the liver that it is difficult to maintain a normal serum testosterone concentration in a hypogonadal man with oral testosterone. The solutions to this problem that have been developed over many years involve modifying the testosterone molecule, changing the method of testosterone delivery, or both.</p><p>A number of <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> preparations are currently available or are under development for treating testosterone deficiency  (<a class="graphic graphic_table graphicRef94118" href="/z/d/graphic/94118.html" rel="external">table 1</a>).</p><p>We usually suggest <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> gels because they typically result in normal and relatively stable serum testosterone concentrations, and most patients prefer them to other preparations. However, other factors affect choice of regimen, including patient preference, cost, convenience, and insurance coverage, which varies by plan and regimen. In general, the newest preparations (the gels) cost the most and injectable esters cost the least.</p><p class="headingAnchor" id="H4105743740"><span class="h3">Topical/transdermal delivery</span></p><p class="bulletIndent1"><span class="glyph">●</span>Three <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> gels (AndroGel, Testim, and Fortesta) and one solution (Axiron) are available. AndroGel is supplied in both 1% and 1.62% concentrations. The 1% concentration was the first to become available. It is still available in 2.5 and 5 g packets, which contain 25 and 50 mg of testosterone, respectively [<a href="#rid18">18,19</a>], and a metered-dose pump that delivers 1.25 g of gel (containing 12.5 mg of testosterone) per pump depression (although the metered-dose pump bottle is no longer available in the United States). When this preparation is applied to the skin once a day in doses of 5 to 10 g (delivering 50 to 100 mg of testosterone), the serum testosterone concentrations usually reach the normal male range within a month and remain steady throughout 24 hours  (<a class="graphic graphic_figure graphicRef74011" href="/z/d/graphic/74011.html" rel="external">figure 1</a>). The serum concentrations of testosterone throughout the 24 hours from one application to the next are similar at one, three, and six months [<a href="#rid20">20</a>]. Occasional local skin irritation occurs but usually does not necessitate discontinuation of therapy  (<a class="graphic graphic_table graphicRef94118" href="/z/d/graphic/94118.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent1">The 1.62% preparation of AndroGel was introduced later and is available in pump bottles. Each depression of the pump bottle yields 1.25 g of gel containing 20.25 mg of <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a>. A study comparing the bioavailability of this preparation at different application sites demonstrated 30 percent lower availability when it was applied to the abdomen than to the arms and shoulders [<a href="#rid21">21</a>]. In another study, administration of 1.25 to 5.0 g a day to men with slightly low serum testosterone concentrations increased the values to within the normal range [<a href="#rid22">22</a>]. In addition to the pump dispenser, AndroGel 1.62% is also available in 20.25 and 40.5 mg packets.</p><p></p><p class="bulletIndent1">Testim (1% <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> gel) is supplied in tubes containing doses of 5 and 10 g, which contain 50 and 100 mg of testosterone, respectively, and when applied daily usually results in normal serum concentrations of testosterone [<a href="#rid23">23</a>]. Anecdotal reports suggest that this preparation gives a musk-like odor  (<a class="graphic graphic_table graphicRef94118" href="/z/d/graphic/94118.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent1">Fortesta (2% <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> gel) is also supplied in a metered-dose pump, with each pump depression delivering 0.5 g of gel (containing 10 mg of testosterone) [<a href="#rid24">24</a>]. The recommended starting dose is 40 mg, applied to the front and inner thighs, and adjusted to a minimum of 10 mg and a maximum of 70 mg, as determined by the serum testosterone concentration. A study in hypogonadal men showed that after 90 days of daily use, the mean serum testosterone concentration before gel application was in the low end of the normal range, after application reached a peak in the mid-normal range in approximately four hours, and fell to the baseline level 12 hours after application  (<a class="graphic graphic_table graphicRef94118" href="/z/d/graphic/94118.html" rel="external">table 1</a>) [<a href="#rid25">25</a>].</p><p></p><p class="bulletIndent1">Axiron (2% <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> solution) is a solution of testosterone that also comes in a metered-dose pump with applicator. Each depression yields 30 mg (1.5 mL) of testosterone. The package insert suggests a starting dose of 30 mg applied to each axilla (total of 60 mg) once a day and adjustment of the dose as low as 30 mg and as high as 120 mg once a day, as judged by the serum testosterone concentration. A study in hypogonadal men treated with 30 to 90 mg of this preparation increased the mean serum testosterone concentration to normal  (<a class="graphic graphic_table graphicRef94118" href="/z/d/graphic/94118.html" rel="external">table 1</a>) [<a href="#rid26">26</a>].</p><p></p><p class="bulletIndent1">Generic versions of most gels are also now available.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Transdermal delivery of <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> first became available in 1994 with the introduction of a scrotal patch (chosen because drugs are absorbed readily across scrotal skin). Since then, body patches and gels have also become available, but the scrotal patch is no longer available in the United States. The major advantage of transdermal administration is maintenance of relatively stable serum testosterone concentrations, resulting in maintenance of relatively stable energy, mood, and libido  (<a class="graphic graphic_table graphicRef94118" href="/z/d/graphic/94118.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>One patch, Androderm, is available in some countries. It is no longer available in the United Kingdom. Androderm relies upon chemical means to increase the absorption of <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> across nongenital skin, and it is meant to be worn on the arm or torso. It delivers approximately 2 or 4 mg of testosterone per 24 hours and results in normal serum testosterone concentrations in the majority of hypogonadal men  (<a class="graphic graphic_figure graphicRef74011" href="/z/d/graphic/74011.html" rel="external">figure 1</a>) [<a href="#rid27">27-30</a>]. Anecdotal reports suggest that as many as one-third of men who try this preparation cannot continue it, because of severe skin rash. A matrix transdermal testosterone patch is available in countries outside of the United States [<a href="#rid31">31</a>].</p><p></p><p class="headingAnchor" id="H5"><span class="h3">Parenteral testosterone</span></p><p class="headingAnchor" id="H1071005154"><span class="h4">Intramuscular injections</span></p><p class="headingAnchor" id="H1198649145"><span class="h5">Long-acting</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">Testosterone</a> enanthate and testosterone cypionate are esters of testosterone that have been used for many years for the treatment of testosterone deficiency. The rationale for their use is that esterification of a lipophilic fatty acid to the 17-beta hydroxyl group of testosterone  (<a class="graphic graphic_figure graphicRef53955" href="/z/d/graphic/53955.html" rel="external">figure 2</a>) makes testosterone even more lipophilic than the native molecule. Intramuscular (IM) injection of testosterone esters results in their storage in and gradual release from the oil-based vehicle in which they are administered, thereby prolonging the presence of testosterone in the blood  (<a class="graphic graphic_table graphicRef94118" href="/z/d/graphic/94118.html" rel="external">table 1</a>) [<a href="#rid32">32,33</a>].</p><p>The therapeutic characteristics of <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> enanthate are relatively well described. In one report, for example, 100 mg of testosterone enanthate was administered once a week for 12 weeks to 12 men with primary hypogonadism [<a href="#rid34">34</a>]. The mean serum testosterone concentration increased to slightly higher than the upper limit of normal one to two days after the injection and gradually decreased to the mid-normal range by the time of the next injection.</p><p>When the dose of <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> was increased to 200 mg in an attempt to prolong the dosing interval to every two weeks, the peak serum testosterone concentration increased further, and the nadir, just before the next injection, decreased to the low-normal range  (<a class="graphic graphic_figure graphicRef74011" href="/z/d/graphic/74011.html" rel="external">figure 1</a>). Regimens of 300 mg every three weeks and 400 mg every four weeks increased the peaks and decreased the nadirs further.</p><p>The serum concentrations of luteinizing hormone (LH), which were initially above normal in all of the men, decreased gradually after initiation of the 100 mg/week regimen and reached the normal range by six to eight weeks. Serum LH concentrations also decreased to normal with the 200 mg per two-week regimen, barely to normal with the 300 mg per three-week regimen, and remained supranormal with the 400 mg per four-week regimen [<a href="#rid34">34</a>].</p><p>These data suggest that <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> enanthate can be administered once every one to two weeks in most men, every three weeks in a few, but not every four weeks. The doses used in this study were all somewhat excessive; we recommend for most men doses of 50 to 100 mg every week or 100 to 200 mg every two weeks.</p><p>Less information is available for <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> cypionate, but the few studies that have been performed suggest that its characteristics are similar to those of testosterone enanthate. Testosterone enanthate has been in short supply in the United States [<a href="#rid35">35</a>], so the cypionate may be the only long-acting ester available in some settings.</p><p>An advantage of <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> enanthate and cypionate over other testosterone preparations is that they are biologically effective in initiating and maintaining normal virilization in all hypogonadal men. Another advantage to some men is freedom from daily administration. The disadvantages are the need for deep IM administration of an oily solution every one to three weeks and fluctuations in the serum testosterone concentration, which result in fluctuations in energy, mood, and libido in many patients. These fluctuations are more pronounced as the dosing interval is increased.</p><p class="headingAnchor" id="H1198649151"><span class="h5">Extra-long-acting</span><span class="headingEndMark"> — </span>An IM formulation of another ester of <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a>, testosterone undecanoate, is available in several countries, including the United States  (<a class="graphic graphic_table graphicRef94118" href="/z/d/graphic/94118.html" rel="external">table 1</a>) [<a href="#rid36">36</a>].</p><p>The prescribing information from the manufacturer for the preparation available in countries other than the United States recommends a dose of 1000 mg administered as a deep IM injection, with a second dose six weeks after the first and subsequent doses every 10 to 14 weeks. One study demonstrated that 1000 mg every three months maintained the mean serum <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> concentration within the normal range for 18 months [<a href="#rid37">37</a>].</p><p>The dosing for the United States preparation is slightly different: each dose is 750 mg in 3 mL of oil injected only into the buttocks. The initial dose is followed by a second dose four weeks later and by subsequent doses every 10 weeks. The extra-long-acting preparations have been associated with rare cases of pulmonary oil microembolism (POME) and anaphylaxis (1.5 and 0.4 cases per 10,000 injections, respectively) [<a href="#rid38">38</a>]. In the United States, the drug is available only through a restricted program called the AVEED Risk Evaluation and Mitigation Strategy (REMS) Program. All injections must be administered in an office or hospital setting by a trained and registered health care provider and monitored for 30 minutes afterwards for adverse reactions.</p><p>Data provided by the manufacturer demonstrate that, after the third injection, the average peak serum <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> value occurs approximately one week after an injection and is followed by a gradual decline until the next injection. The serum testosterone concentration at approximately five weeks would provide an approximate average for the interdosing period.</p><p>Because of the inconvenience of injecting a large volume of oil in a restricted setting and the lack of flexibility in dosing, we suggest this preparation only for patients who do not have access to, or do not care for, other forms of <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> treatment and who do have access to a registered clinic and provider.</p><p class="headingAnchor" id="H462083696"><span class="h4">Subcutaneous injection</span><span class="headingEndMark"> — </span>A formulation of <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> enanthate for subcutaneous injection by autoinjector once a week is now available [<a href="#rid39">39</a>]. Insufficient information is available about its use in men with marked hypogonadism to recommend its routine use yet. Of note, subcutaneous testosterone has been used for the management of transgender men. (See  <a class="medical medical_review" href="/z/d/html/109911.html" rel="external">"Transgender men: Evaluation and management", section on 'Testosterone therapy'</a>.)</p><p class="headingAnchor" id="H3279516134"><span class="h3">Oral preparations</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Methyltestosterone</strong> – Several 17-alpha alkylated androgens (eg, <a class="drug drug_general" data-topicid="9640" href="/z/d/drug information/9640.html" rel="external">methyltestosterone</a>) have been available for oral use for many years, but we suggest <strong>not</strong> using them. Decades ago, investigators discovered that adding an alkyl group in the 17-alpha position of the <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> molecule slowed its catabolism by the liver  (<a class="graphic graphic_figure graphicRef53955" href="/z/d/graphic/53955.html" rel="external">figure 2</a>). Many endocrinologists who treat male hypogonadism think that these preparations are not fully effective in producing virilization, although no studies have tested these observations. In addition, several reports have described hepatic side effects with these preparations, including cholestatic jaundice, a hepatic cystic disease called peliosis hepatis, and hepatoma [<a href="#rid40">40-44</a>]. For both of these reasons and because better preparations are available, the 17-alpha alkylated androgens should generally <strong>not </strong>be used to treat testosterone deficiency.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral </strong><strong>testosterone</strong><strong> undecanoate</strong> – Several oral <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> preparations (testosterone undecanoate) are now available in a number of countries [<a href="#rid45">45,46</a>]. They are lipophilic, absorbed through the intestinal lymphatic system, and, unlike previous oral testosterone preparations, bypasses the first-pass hepatic effect. The product includes a warning about possible increases in blood pressure and cardiovascular events (myocardial infarction, stroke). A major concern is its potential inappropriate use in older men with age-related low testosterone; the risks likely outweigh the benefits in these patients  (<a class="graphic graphic_table graphicRef94118" href="/z/d/graphic/94118.html" rel="external">table 1</a>).</p><p></p><p class="headingAnchor" id="H69695579"><span class="h3">Other</span></p><p class="bulletIndent1"><span class="glyph">●</span>A buccal tablet (Striant SR) is no longer available in the United States  (<a class="graphic graphic_table graphicRef94118" href="/z/d/graphic/94118.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A subcutaneous <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> pellet (Testopel) is available. The recommended dosing is two to six 75 mg testosterone pellets every three to six months. The pellets are implanted into the subdermal fat of the buttocks, lower abdominal wall, or thigh with a trocar under sterile conditions using a local anesthetic [<a href="#rid47">47</a>]. Adverse events include pellet extrusion, infection, and fibrosis. Because of the need for surgery to insert them and the limited data on the serum testosterone concentrations during treatment, we do not routinely recommend this preparation  (<a class="graphic graphic_table graphicRef94118" href="/z/d/graphic/94118.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A nasal <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> gel (Natesto) is now approved in the United States for the treatment of male hypogonadism [<a href="#rid48">48</a>]. The gel is administered into the nostrils via a metered-dose pump applicator. One pump actuation delivers 5.5 mg of testosterone; the recommended dose is 11 mg (two pump actuations, one in each nostril), three times daily (total 33 mg/day). One advantage over other formulations is the minimal risk of gel transfer to a partner or child. On the other hand, some men may find the three times daily regimen inconvenient, and men with allergies or underlying nasal or sinus pathology may have trouble tolerating the formulation as ≥3 percent of subjects in clinical trials experienced rhinorrhea, epistaxis, nasopharyngitis, sinusitis, and nasal scab. Lastly, data in mice show brain levels of testosterone that are twice as high with the nasal gel as with intravenous testosterone. It is not known if this occurs in men treated with the nasal gel. Until further published data are available, we suggest using the available testosterone gels, patch, or injectable esters over this new formulation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Human chorionic gonadotropin (hCG), while not an androgen, stimulates the testes to make <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> and is especially useful in stimulating both testosterone and sperm production. It is given by subcutaneous or IM injections two to three times weekly. (See  <a class="medical medical_review" href="/z/d/html/7463.html" rel="external">"Induction of fertility in males with secondary hypogonadism"</a>.)</p><p></p><p class="headingAnchor" id="H2364392919"><span class="h2">Suppression of spermatogenesis</span><span class="headingEndMark"> — </span>Administration of <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> exogenously suppresses LH secretion and thereby suppresses the high concentration of intratesticular testosterone essential for spermatogenesis [<a href="#rid49">49</a>]. Although the effect of replacement doses of testosterone in men with mild degrees of hypogonadism who still have some degree of spermatogenesis has not been studied, hypogonadal men who are being considered for testosterone replacement should be told of the suppressive effect of testosterone on spermatogenesis and asked if they desire fertility. If they do, other treatments should be considered. (See  <a class="medical medical_review" href="/z/d/html/7452.html" rel="external">"Treatments for male infertility"</a> and  <a class="medical medical_review" href="/z/d/html/7463.html" rel="external">"Induction of fertility in males with secondary hypogonadism"</a>.)</p><p class="headingAnchor" id="H1778680472"><span class="h3">Exogenous testosterone for hormonal contraception</span><span class="headingEndMark"> — </span>Choices for male contraception are currently limited (condoms and vasectomy), but there have been ongoing attempts to develop a hormonal male contraceptive. Supraphysiologic doses of exogenous <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> suppress spermatogenesis, but earlier and more complete suppression to azoospermia or near-azoospermia can be achieved with replacement doses of testosterone combined with a progestin [<a href="#rid50">50</a>]. In a new multicenter study of 320 normal men receiving a long-acting, combination regimen (testosterone undecanoate [1000 mg] and norethisterone enanthate [200 mg]) administered IM every eight weeks, 96 percent of continuing users suppressed to a sperm concentration ≤1 million/mL within 24 weeks [<a href="#rid51">51</a>]. Contraceptive efficacy in the men who suppressed sperm concentration ≤1 million/mL over 56 weeks was 98.4 percent (four pregnancies in 266 continuing participants), a rate similar to some female contraceptive methods (see  <a class="medical medical_review" href="/z/d/html/5459.html" rel="external">"Contraception: Counseling and selection"</a>). Recovery of normal spermatogenesis after 52 weeks was 95 percent in continuing users. An external safety review committee recommended early termination of this trial because it concluded the risks of continuing outweighed the possible benefits. The adverse events of concern were mood changes, depression, pain at the injection site, and increased libido.</p><p class="headingAnchor" id="H165683037"><span class="h2">Contraindications to use</span><span class="headingEndMark"> — </span>Several possible contraindications to <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> therapy should be evaluated before initiating testosterone treatment:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prostate cancer</strong> – A man who has a history of prostate cancer should generally not be treated with <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a>. A possible exception is a hypogonadal man who had a radical prostatectomy for cancer confined to the prostate and has been free of disease and has had an undetectable prostate-specific antigen (PSA) for at least two years [<a href="#rid2">2,52</a>].</p><p></p><p class="bulletIndent1">The use of <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> replacement therapy in prostate cancer survivors with hypogonadism due to prior androgen deprivation therapy is controversial. This topic is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/14235.html" rel="external">"Overview of approach to prostate cancer survivors"</a>.)</p><p></p><p class="bulletIndent1">Other men should be evaluated for the possibility of previously undiagnosed prostate cancer. A man over 50 years (or over 40 years if he is African American or has a history of prostate cancer in a first-degree relative) should have a digital rectal examination and a serum PSA measurement. If a prostate nodule is detected or the PSA is &gt;4 ng/mL or &gt;3 ng/mL in a man of high risk, the man should be referred for urologic consultation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Breast cancer</strong> – <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">Testosterone</a> is aromatized to estradiol, so men who have breast cancer should not be treated with testosterone.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lower urinary tract symptoms (LUTS) that are severe  (<a class="graphic graphic_table graphicRef57680" href="/z/d/graphic/57680.html" rel="external">table 2</a>). LUTS should be assessed by the International Prostate Symptom Score (IPSS)  (<a class="graphic graphic_table graphicRef57680" href="/z/d/graphic/57680.html" rel="external">table 2</a>) [<a href="#rid53">53</a>]. If warranted by symptoms, the urine flow rate [<a href="#rid54">54</a>] and post-void residual urine in the bladder by ultrasonography [<a href="#rid55">55</a>] should be measured before beginning treatment (see  <a class="medical medical_review" href="/z/d/html/6889.html" rel="external">"Clinical manifestations and diagnostic evaluation of benign prostatic hyperplasia"</a>). Moderate or severe LUTS (eg, score &gt;19) due to benign prostatic hyperplasia (BPH) should be treated before beginning <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> replacement. (See  <a class="medical medical_review" href="/z/d/html/6891.html" rel="external">"Medical treatment of benign prostatic hyperplasia"</a> and  <a class="medical medical_review" href="/z/d/html/8093.html" rel="external">"Surgical treatment of benign prostatic hyperplasia (BPH)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Erythrocytosis, eg hematocrit &gt;50 percent. <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">Testosterone</a> stimulates erythropoiesis, so the hematocrit should be measured before initiating testosterone treatment, and if it is elevated, the cause should be sought and the condition treated before testosterone treatment is initiated.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sleep apnea that is severe and untreated (see  <a class="medical medical_review" href="/z/d/html/7706.html" rel="external">"Clinical presentation and diagnosis of obstructive sleep apnea in adults"</a>) may be worsened [<a href="#rid2">2</a>]; the clinician should inquire about symptoms, such as excessive daytime sleepiness and apnea witnessed during sleep by a partner. If indicated, polysomnography should be performed (see  <a class="medical medical_review" href="/z/d/html/7706.html" rel="external">"Clinical presentation and diagnosis of obstructive sleep apnea in adults"</a>). Patients whose sleep apnea is well treated with continuous positive airway pressure (CPAP) may take <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> treatment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Uncontrolled heart failure [<a href="#rid56">56</a>]. <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">Testosterone</a> has slight sodium retaining properties, so severe heart failure should be treated before beginning testosterone treatment.</p><p></p><p class="headingAnchor" id="H165683108"><span class="h2">Monitoring</span></p><p class="headingAnchor" id="H165682327"><span class="h3">Is the testosterone dose therapeutic?</span></p><p class="headingAnchor" id="H165683176"><span class="h4">Serum testosterone concentration</span><span class="headingEndMark"> — </span>Patients who are treated with <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> should be monitored to determine that normal serum testosterone concentrations are being achieved. Monitoring should be done two to three months after initiation of treatment and after changing a dose. When the dose appears to be stable, monitoring every 6 to 12 months should suffice. They should also be monitored for undesirable effects.</p><p>The timing of serum <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> measurements varies with the preparation that is used.</p><p class="bulletIndent1"><span class="glyph">●</span>Serum <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> should be measured midway between injections in men who are receiving testosterone enanthate or cypionate, and the value should be mid-normal, eg, 500 to 600 ng/dL (17.3 to 20.8 nmol/L). The dose should be reduced if higher values are obtained.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The serum <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> can be measured at any time in men who are using any of the transdermal preparations, with the recognition that the peak values occur six to eight hours after application of the patch.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> concentrations vary substantially when a <strong>gel </strong>is used but not in a predictable way. Therefore, we suggest two serum testosterone measurements before making dose adjustments [<a href="#rid57">57</a>]. This was illustrated in a study of 47 hypogonadal men ≥65 years (27 receiving testosterone gel and 20 on placebo gel); two outpatient, two-hour post-application testosterone levels were significantly but not highly correlated (the correlation coefficient was 0.67). The therapeutic goal should be a testosterone value well within the normal range (400 to 700 ng/dL [13.9 to 24.3 nmol/L]). Patients can have the two samples obtained with as many days between as fits their schedules. Ideally, the two samples should be obtained before the outpatient visit, so the results are available at the time of the visit.</p><p></p><p class="bulletIndent1">Although it is ideal to measure <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> twice before making dose adjustments, a single measurement represents an improvement over typical practice as 50 percent of men prescribed testosterone have <strong>no</strong> biochemical monitoring for the first six months [<a href="#rid58">58</a>].</p><p></p><p>If the patient has primary hypogonadism, normalization of the serum LH concentration should also be used to judge the adequacy of the <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> dose no matter which testosterone preparation is used.</p><p class="headingAnchor" id="H165683169"><span class="h4">Bone density</span><span class="headingEndMark"> — </span>If a bone fracture or bone density in the osteoporotic range was a presenting finding of hypogonadism, bone density should be reassessed every two years until it becomes normal or stabilizes. If it stabilizes and is still in the osteoporotic range, pharmacologic treatment for osteoporosis should be initiated.</p><p class="headingAnchor" id="H165682339"><span class="h3">Potential adverse effects</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">Testosterone</a> enanthate and the testosterone patch and gels have few side effects unrelated to the action of testosterone. Some of the actions of testosterone itself, while not side effects, are undesirable.</p><p class="headingAnchor" id="H165681898"><span class="h4">Prostate cancer</span><span class="headingEndMark"> — </span>Prostate volumes and serum PSA increase in response to <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> treatment [<a href="#rid59">59-61</a>]. On average, values increase to those of age-matched eugonadal men [<a href="#rid62">62</a>]. Because prostate cancer is, at least to some degree, testosterone dependent, it seems theoretically likely that the risk of prostate cancer is less in hypogonadal men than in eugonadal men and that the risk increases to normal, but not above, when testosterone is replaced. However, data to support or refute this assumption are limited [<a href="#rid63">63,64</a>]. It seems prudent, nonetheless, to monitor hypogonadal men for prostate cancer after beginning testosterone replacement, just as one would monitor a eugonadal man. (See  <a class="medical medical_review" href="/z/d/html/7457.html" rel="external">"Approach to older males with low testosterone"</a>.)</p><p>We agree with the Endocrine Society guidelines [<a href="#rid2">2</a>] that men over age 50 years (or 40 years if they are at high risk) who begin <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> treatment should be reevaluated for prostate cancer three months and one year after beginning treatment and thereafter according to the standard of care. A patient should be referred for urologic consultation if a prostate nodule is palpated or the serum PSA concentration (confirmed by a repeat value) rises by more than 1.4 ng/mL in any one-year period or to &gt;4 ng/mL.</p><p class="headingAnchor" id="H2970390049"><span class="h4">Benign prostatic hyperplasia (BPH)</span><span class="headingEndMark"> — </span>Because BPH is a testosterone-dependent disease [<a href="#rid65">65</a>], there is a theoretical reason for concern that <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> treatment might increase BPH and worsen urinary outflow obstruction and LUTS. (See  <a class="medical medical_review" href="/z/d/html/6889.html" rel="external">"Clinical manifestations and diagnostic evaluation of benign prostatic hyperplasia"</a>.)</p><p>However, in a 2018 meta-analysis of trials of <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> therapy in 1771 hypogonadal men, no significant effects of testosterone were seen on LUTS when compared with the placebo/nonintervention group [<a href="#rid66">66</a>]. In the 788 men 65 years and older enrolled in the Testosterone Trials who were treated with testosterone or placebo for one year, there was no difference in change in the IPSS between the two treatment groups [<a href="#rid11">11</a>].</p><p class="headingAnchor" id="H165681927"><span class="h4">Erythrocytosis</span><span class="headingEndMark"> — </span>Erythrocytosis is a common adverse effect of <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> administration, particularly with testosterone ester injections [<a href="#rid67">67,68</a>]. It is of concern because the risk of venous thromboembolic disease is directly related to hematocrit [<a href="#rid69">69</a>]. In a meta-analysis of three placebo-controlled clinical trials that enrolled a total of 1543 participants, erythrocytosis occurred in 16 men in the testosterone arms compared with one man in the placebo arms [<a href="#rid66">66</a>].</p><p>The hematocrit should be measured after three to six months after initiating <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> treatment and then yearly. If it increases above the upper limit of normal, a cause should be sought, and if none is found, the dose of testosterone should be decreased or stopped. The Endocrine Society guidelines suggest stopping therapy if the hematocrit increases to ≥54 percent [<a href="#rid2">2</a>]. The hematocrit should be reevaluated two months after the decrease or discontinuation. If the hematocrit normalizes, a lower dose of testosterone should be continued or restarted. If the hematocrit cannot be kept below the upper limit of normal, even when the serum testosterone concentration is at the low end of the normal range during testosterone treatment, the patient should be evaluated for hypoxia and sleep apnea. If no treatable cause is found, phlebotomy can be considered.</p><p class="headingAnchor" id="H1137239510"><span class="h4">Venous thromboembolism</span><span class="headingEndMark"> — </span>Standard labeling of <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> products in the United States has included information about the risk of venous thromboembolism (VTE) as a consequence of erythrocytosis (see <a class="local">'Erythrocytosis'</a> above). However, after reports of deep venous thromboses and pulmonary emboli <strong>unrelated</strong> to polycythemia in men taking testosterone [<a href="#rid70">70</a>], the US Food and Drug Administration (FDA) now requires a more general warning in the labeling of all approved testosterone products [<a href="#rid71">71</a>]. In one study, 39 of 40 cases of VTE in men taking testosterone were associated with a previously undiagnosed thrombophilia-hypofibrinolysis, highlighting the importance of a careful personal and family VTE history prior to initiating treatment. Routine screening for thrombophilias in men considering testosterone therapy is not currently suggested.</p><p class="headingAnchor" id="H12677173"><span class="h4">Cardiovascular risks</span><span class="headingEndMark"> — </span>The Endocrine Society [<a href="#rid72">72</a>] and the FDA have issued statements alerting clinicians to the potential concerns about <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> therapy and cardiovascular safety. Based upon available data, the FDA has concluded that, despite conflicting and inconclusive evidence, there is a possibility of increased cardiovascular risk associated with testosterone use. Therefore, they are requiring that manufacturers of approved testosterone products change their labeling to clarify the approved uses of testosterone (see <a class="local">'Appropriate candidates'</a> above) and to add information about the possibility of increased risks of myocardial infarctions (MIs) and strokes in patients taking testosterone [<a href="#rid73">73</a>].</p><p><a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">Testosterone</a> treatment of hypogonadal men has generally not been associated with increased cardiovascular risk, as shown by an observational study [<a href="#rid74">74</a>], a meta-analysis of 51 clinical trials that included seven trials with the outcome of MI (n = 1053 patients, relative risk [RR] 0.91) [<a href="#rid67">67</a>] and a randomized trial published after data were analyzed for the meta-analysis [<a href="#rid75">75</a>]. The meta-analysis, however, was done in men of variable ages and baseline risk for cardiovascular disease; some of the included trials were done in older men, while others were done in considerably younger human immunodeficiency virus (HIV)-positive men. A subgroup analysis in men over age 65 years was reassuring as no increase in cardiovascular events was noted in those taking testosterone compared with placebo [<a href="#rid67">67</a>].</p><p>The impact of <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> on subclinical atherosclerosis in older men was addressed in the Testosterone's Effects on Atherosclerosis Progression in Aging Men (TEAAM) trial, a study of 308 men ≥60 years with low or low-normal serum testosterone concentrations (100 to 400 ng/dL [3.5 to 13.9 nmol/L], free testosterone &lt;50 pg/mL [0.17 nmol/L]) who were randomly assigned to three years of testosterone gel (1%, 7.5 g) or placebo gel [<a href="#rid76">76</a>]. Mean serum testosterone concentration was significantly higher in the treatment group compared with the placebo group (565 and 330 ng/dL [19.6 and 11.4 nmol/L], respectively), but the rates of change in carotid intima-media thickness and coronary artery calcium scores (markers of subclinical atherosclerosis) were not significantly different. While it is reassuring that testosterone therapy did not accelerate progression of subclinical atherosclerosis, a much larger trial looking at clinical cardiovascular events would be needed to establish cardiovascular safety [<a href="#rid77">77-79</a>].</p><p>However, other evidence has raised concern for possible excess cardiovascular risk among some groups of men receiving <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> therapy, as illustrated by the following findings:</p><p class="bulletIndent1"><span class="glyph">●</span>A randomized trial of <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> therapy in older men (Testosterone in Older Men With Sarcopenia [TOM] trial) (mean age 74 years) with mobility limitation and a high prevalence of chronic disease was stopped early, due to the higher frequency of self-reported, cardiovascular-related adverse events (that were not prespecified outcomes) in men assigned to the testosterone arm compared with the placebo arm [<a href="#rid80">80</a>]. Because the trial was stopped early and because no single adverse event was predominant, it is difficult to draw firm conclusions about the effect of testosterone therapy on cardiovascular risks in this population. In addition, another randomized trial in a similar number of men, also with mild degree of frailty, reported no excess of cardiovascular events [<a href="#rid75">75</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the 788 men of average age 72 years enrolled in the <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">Testosterone</a> Trials and treated with testosterone or placebo for one year, the number of major adverse cardiovascular events was similar in the testosterone and placebo arms [<a href="#rid11">11</a>]. However, in a subset of men who participated in the cardiovascular trial of the Testosterone Trials, noncalcified coronary artery plaque volume, as determined by computed tomographic angiography, increased by 40 mm<sup>3</sup> (95% CI 23-56) in 73 men treated with testosterone compared with 4 mm<sup>3</sup> (95% CI -14 to 22) (p = 0.003) in 65 men treated with placebo [<a href="#rid81">81</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective cohort study of 8709 men ages 60 to 64 years with low serum <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> concentrations (&lt;300 ng/dL [10.4 nmol/L]) undergoing coronary angiography, men who were subsequently prescribed testosterone had a higher risk of a composite outcome of all-cause mortality, MI, and stroke than men who did not take testosterone (hazard ratio [HR] 1.29, 95% CI 1.04-1.58); the results were similar after adjusting for the presence of coronary artery disease (CAD) [<a href="#rid82">82</a>]. Although the difference was significant, the absolute risk difference after one year of treatment was only 1.3 percent (11.3 versus 10 percent of patients had events in the testosterone and nontestosterone groups, respectively). A high percentage of men in the cohort had comorbidities, including over 80 percent with CAD. Men were prescribed testosterone gels, injections, but most commonly, patches.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A second retrospective cohort study examined records of 55,593 men who had been prescribed <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> therapy. They found an increase in the RR of MI in men in the three months after starting testosterone therapy when compared with the rate of MI in the prior year (RR 1.36) [<a href="#rid83">83</a>]. However, the absolute excess risk was very low: an additional 1.25 cases per 1000 patient-years. The increase in MIs was more pronounced in men over age 65 years (RR 2.19, absolute increase 6.25 versus 0.5 additional cases per 1000 patient-years for those under age 65 years). In addition, men under age 65 years with known heart disease were at increased risk for MI (RR 2.07, absolute excess risk 10 additional cases per 1000 patient-years). Pretreatment serum testosterone concentration was not one of the factors for inclusion in this study, so it is not known if the men were hypogonadal.</p><p></p><p>Both retrospective studies [<a href="#rid82">82,83</a>] are limited by the inability to verify diagnoses, indications for <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> therapy, testosterone dose, and information on serum testosterone concentrations immediately before initiating therapy and during therapy. The lack of documentation of antecedent hypogonadism is particularly important because of the widespread and often inappropriate prescription of testosterone therapy for men with normal age-associated symptoms who do <strong>not</strong> have hypogonadism. (See <a class="local">'Inappropriate use of testosterone in healthy, middle-aged men'</a> above.)</p><p>The route of <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> administration may be associated with risk. In a retrospective analysis of three databases that included over 544,000 men receiving newly prescribed testosterone therapy, use of injectable testosterone preparations (which result in intermittent supraphysiologic serum testosterone concentrations) was associated with a greater risk of MI (HR 1.30, 95% CI 1.18-1.45) and stroke (HR 1.21, 95% CI 1.10-1.32), but not VTE (HR 0.92), when compared with testosterone gel use [<a href="#rid84">84</a>]. Of note, this study did not assess the safety of testosterone therapy in users versus nonusers, nor did it provide information on indications for testosterone therapy. The absolute increased risks of MI and stroke were low (1 and 5 additional events/1000 patient-years for men in their 50s or over age 65 years, respectively). These data do not change our management approach. We typically suggest testosterone gels, but some patients prefer injectables because of lower cost and convenience. (See <a class="local">'Choice of testosterone regimen'</a> above.)</p><p>We continue to recommend that <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> be administered <strong>only</strong> <strong>to men who are hypogonadal</strong>, as evidenced by clinical symptoms and signs consistent with androgen deficiency and a subnormal morning serum testosterone concentration on three occasions, as outlined above. The beneficial effects of testosterone in these men are clear, and there is no reason to suspect that increasing the serum testosterone to normal would increase the risk of any condition above normal. (See <a class="local">'Appropriate candidates'</a> above.)</p><p class="headingAnchor" id="H165681933"><span class="h4">Skin irritation</span><span class="headingEndMark"> — </span>The patch Androderm often causes skin rashes, some very mild and others quite severe, requiring discontinuation of this treatment. The rash may sometimes be prevented by pretreatment of the skin with a corticosteroid cream [<a href="#rid85">85</a>]. This patch has been taken off the market in some countries.</p><p>Local skin irritation occasionally occurs with <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> gels (AndroGel and Testim) but usually is not severe and does not necessitate discontinuation of therapy.</p><p class="headingAnchor" id="H23"><span class="h4">Secondary exposure: Minimal risk with precautions</span><span class="headingEndMark"> — </span>With <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> gels, the possibility of skin transfer to another person is very low if the patient follows the package insert directions that include:</p><p class="bulletIndent1"><span class="glyph">●</span>Washing hands thoroughly after application</p><p class="bulletIndent1"><span class="glyph">●</span>Avoiding skin contact until the gel has dried completely</p><p class="bulletIndent1"><span class="glyph">●</span>Avoiding getting the site wet for approximately five hours after application</p><p></p><p>In a study of healthy male volunteers receiving <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> gel, intense skin contact with a second male volunteer (pretreated with norethisterone [400 mg IM] to suppress endogenous testosterone) did not result in an increase in serum testosterone concentrations [<a href="#rid86">86</a>].</p><p>However, the FDA has mandated a boxed warning for all <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> gel products after receiving reports of secondary exposure in eight children ages nine months to five years [<a href="#rid87">87,88</a>]. Exposure resulted in penile or clitoral enlargement, premature development of pubic hair, advanced bone age, increased libido, and aggressive behavior, most of which regressed when the child was no longer exposed to testosterone (with the exception of penile/clitoral enlargement).</p><p>These complications are extremely rare (8 cases per 1.8 million prescriptions), and therefore, <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> gel use should still be considered safe [<a href="#rid88">88</a>]. However, it is extremely important to take precautions to avoid contact transfer of testosterone, eg, by washing hands after application and keeping the application site covered with clothing.</p><p class="headingAnchor" id="H4062032256"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/115296.html" rel="external">"Society guideline links: Testosterone therapy in men"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/115208.html" rel="external">"Society guideline links: Male infertility or hypogonadism"</a>.)</p><p class="headingAnchor" id="H1119454898"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/86221.html" rel="external">"Patient education: Androgen replacement in men (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/88640.html" rel="external">"Patient education: Low testosterone in men (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H25"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Candidates for </strong><a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a><strong>: Hypogonadal men</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hypogonadal men</strong> – For hypogonadal men (with signs and symptoms of <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> deficiency such as low libido, decreased morning erections, loss of body hair, low bone mineral density, gynecomastia, and small testes) and a subnormal morning (8 to 10 AM) serum testosterone concentration on two to three separate occasions, we suggest testosterone replacement therapy (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Appropriate candidates'</a> above.)</p><p></p><p class="bulletIndent2">The main goal of <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> therapy is to restore the serum testosterone concentration to the normal (eugonadal) range. (See <a class="local">'General principles'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Inappropriate use of </strong><a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a><strong> therapy</strong> – There has been a dramatic increase in inappropriate use of testosterone therapy in healthy, middle-aged and older men. Testosterone should not be prescribed for men with vague symptoms (such as fatigue) (see <a class="local">'Inappropriate use of testosterone in healthy, middle-aged men'</a> above) and a single low serum testosterone concentration (rather than two to three as recommended).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">Testosterone</a><strong> preparations</strong> – A number of testosterone preparations are currently available for treating testosterone deficiency  (<a class="graphic graphic_table graphicRef94118" href="/z/d/graphic/94118.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent1">We usually start with <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> gels because they typically result in normal and relatively stable serum testosterone concentrations, and most patients prefer them to other preparations. However, some patients prefer parenteral formulations. Other factors that affect choice of regimen include patient preference, cost, convenience, and insurance coverage, which is variable. (See <a class="local">'Choice of testosterone regimen'</a> above.)</p><p></p><p class="bulletIndent1">Dosing for different formulations is described above  (<a class="graphic graphic_table graphicRef94118" href="/z/d/graphic/94118.html" rel="external">table 1</a>). (See <a class="local">'Choice of testosterone regimen'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Potential adverse effects</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Erythrocytosis</strong> – <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">Testosterone</a> therapy is associated with erythrocytosis, more often with parenteral preparations. A hematocrit should be measured three to six months after initiating therapy, and if normal, it can be measured yearly. Clinical guidelines suggest stopping therapy if the hematocrit increases to ≥54 percent; the hematocrit should be reevaluated two months after the decrease or discontinuation. If the hematocrit normalizes, a lower dose of testosterone can be continued or restarted. (See <a class="local">'Erythrocytosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other</strong> – The impact of <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> therapy on prostate cancer risk and symptoms of benign prostatic hyperplasia are somewhat unclear. In addition, cardiovascular risks are uncertain. Theoretically, restoring normal levels of testosterone in a formerly hypogonadal male should not increase these risks above those observed in eugonadal men. (See <a class="local">'Potential adverse effects'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring treatment</strong> – Patients who are treated with <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> should be monitored for any adverse effects and to determine that normal serum testosterone concentrations are being achieved. Monitoring should be done two to three months after initiation of treatment and after changing a dose. When the dose appears to be stable, monitoring can be done every 6 to 12 months. (See <a class="local">'Is the testosterone dose therapeutic?'</a> above.)</p><p></p><p class="bulletIndent1">Serum <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> should be measured midway between injections in men who are receiving parenteral testosterone (testosterone enanthate or cypionate), and the value should be mid-normal, eg, 500 to 600 ng/dL (17.3 to 20.8 nmol/L). The dose should be reduced if higher values are obtained.</p><p></p><p class="bulletIndent1">Serum <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> concentrations vary substantially when a <strong>gel </strong>is used. Ideally, two samples for testosterone should be measured after a dose before making any adjustments. However, in practice, many clinicians are only able to obtain one sample.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Finkelstein JS, Lee H, Burnett-Bowie SA, et al. Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med 2013; 369:1011.</a></li><li><a class="nounderline abstract_t">Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2018; 103:1715.</a></li><li><a class="nounderline abstract_t">Bhasin S, Storer TW, Berman N, et al. Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab 1997; 82:407.</a></li><li><a class="nounderline abstract_t">Behre HM, Kliesch S, Leifke E, et al. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 1997; 82:2386.</a></li><li><a class="nounderline abstract_t">Jockenhövel F, Minnemann T, Schubert M, et al. Comparison of long-acting testosterone undecanoate formulation versus testosterone enanthate on sexual function and mood in hypogonadal men. Eur J Endocrinol 2009; 160:815.</a></li><li><a class="nounderline abstract_t">Bhasin S, Woodhouse L, Casaburi R, et al. Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle. J Clin Endocrinol Metab 2005; 90:678.</a></li><li><a class="nounderline abstract_t">Bhasin S, Woodhouse L, Casaburi R, et al. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab 2001; 281:E1172.</a></li><li><a class="nounderline abstract_t">Vaughan C, Goldstein FC, Tenover JL. Exogenous testosterone alone or with finasteride does not improve measurements of cognition in healthy older men with low serum testosterone. J Androl 2007; 28:875.</a></li><li><a class="nounderline abstract_t">Snyder PJ, Peachey H, Berlin JA, et al. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 2000; 85:2670.</a></li><li><a class="nounderline abstract_t">Caronia LM, Dwyer AA, Hayden D, et al. Abrupt decrease in serum testosterone levels after an oral glucose load in men: implications for screening for hypogonadism. Clin Endocrinol (Oxf) 2013; 78:291.</a></li><li><a class="nounderline abstract_t">Snyder PJ, Bhasin S, Cunningham GR, et al. Effects of Testosterone Treatment in Older Men. N Engl J Med 2016; 374:611.</a></li><li><a class="nounderline abstract_t">Morales A, Bebb RA, Manjoo P, et al. Diagnosis and management of testosterone deficiency syndrome in men: clinical practice guideline. CMAJ 2015; 187:1369.</a></li><li><a class="nounderline abstract_t">Baillargeon J, Urban RJ, Ottenbacher KJ, et al. Trends in androgen prescribing in the United States, 2001 to 2011. JAMA Intern Med 2013; 173:1465.</a></li><li><a class="nounderline abstract_t">Braun SR. Promoting "low T": a medical writer's perspective. JAMA Intern Med 2013; 173:1458.</a></li><li><a class="nounderline abstract_t">Schwartz LM, Woloshin S. Low "T" as in "template": how to sell disease. JAMA Intern Med 2013; 173:1460.</a></li><li><a class="nounderline abstract_t">Handelsman DJ. Global trends in testosterone prescribing, 2000-2011: expanding the spectrum of prescription drug misuse. Med J Aust 2013; 199:548.</a></li><li><a class="nounderline abstract_t">Layton JB, Kim Y, Alexander GC, Emery SL. Association Between Direct-to-Consumer Advertising and Testosterone Testing and Initiation in the United States, 2009-2013. JAMA 2017; 317:1159.</a></li><li><a class="nounderline abstract_t">Wang C, Berman N, Longstreth JA, et al. Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a General Clinical Research Center Study. J Clin Endocrinol Metab 2000; 85:964.</a></li><li><a class="nounderline abstract_t">Androgel. Med Lett Drugs Ther 2000; 42:49.</a></li><li><a class="nounderline abstract_t">Swerdloff RS, Wang C, Cunningham G, et al. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J Clin Endocrinol Metab 2000; 85:4500.</a></li><li><a class="nounderline abstract_t">Miller J, Britto M, Fitzpatrick S, et al. Pharmacokinetics and relative bioavailability of absorbed testosterone after administration of a 1.62% testosterone gel to different application sites in men with hypogonadism. Endocr Pract 2011; 17:574.</a></li><li><a class="nounderline abstract_t">Kaufman JM, Miller MG, Garwin JL, et al. Efficacy and safety study of 1.62% testosterone gel for the treatment of hypogonadal men. J Sex Med 2011; 8:2079.</a></li><li><a class="nounderline abstract_t">McNicholas TA, Dean JD, Mulder H, et al. A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function. BJU Int 2003; 91:69.</a></li><li><a class="nounderline abstract_t">A new testosterone gel (fortesta) for hypogonadism. Med Lett Drugs Ther 2011; 53:29.</a></li><li><a class="nounderline abstract_t">Dobs AS, McGettigan J, Norwood P, et al. A novel testosterone 2% gel for the treatment of hypogonadal males. J Androl 2012; 33:601.</a></li><li><a class="nounderline abstract_t">Wang C, Ilani N, Arver S, et al. Efficacy and safety of the 2% formulation of testosterone topical solution applied to the axillae in androgen-deficient men. Clin Endocrinol (Oxf) 2011; 75:836.</a></li><li><a class="nounderline abstract_t">Meikle AW, Mazer NA, Moellmer JF, et al. Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men. J Clin Endocrinol Metab 1992; 74:623.</a></li><li><a class="nounderline abstract_t">Meikle AW, Arver S, Dobs AS, et al. Pharmacokinetics and metabolism of a permeation-enhanced testosterone transdermal system in hypogonadal men: influence of application site- -a clinical research center study. J Clin Endocrinol Metab 1996; 81:1832.</a></li><li><a class="nounderline abstract_t">Brocks DR, Meikle AW, Boike SC, et al. Pharmacokinetics of testosterone in hypogonadal men after transdermal delivery: influence of dose. J Clin Pharmacol 1996; 36:732.</a></li><li><a class="nounderline abstract_t">Dobs AS, Meikle AW, Arver S, et al. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab 1999; 84:3469.</a></li><li><a class="nounderline abstract_t">Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010; 95:2536.</a></li><li><a class="nounderline abstract_t">Behre HM, Abshagen K, Oettel M, et al. Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies. Eur J Endocrinol 1999; 140:414.</a></li><li><a class="nounderline abstract_t">Fujioka M, Shinohara Y, Baba S, et al. Pharmacokinetic properties of testosterone propionate in normal men. J Clin Endocrinol Metab 1986; 63:1361.</a></li><li><a class="nounderline abstract_t">Snyder PJ, Lawrence DA. Treatment of male hypogonadism with testosterone enanthate. J Clin Endocrinol Metab 1980; 51:1335.</a></li><li class="breakAll">Testosterone Enanthate Injection.  Current Drug Shortages. American Society of Health System Pharmacists. http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=1045 (Accessed on April 22, 2014).</li><li class="breakAll">http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails (Accessed on March 11, 2014).</li><li><a class="nounderline abstract_t">Schubert M, Minnemann T, Hübler D, et al. Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. J Clin Endocrinol Metab 2004; 89:5429.</a></li><li class="breakAll">http://www.scribd.com/doc/211471259/69/Overlap-of-Cases-Adjudicated-as-POME-and-Anaphylaxis (Accessed on March 11, 2014).</li><li><a class="nounderline abstract_t">Kaminetsky JC, McCullough A, Hwang K, et al. A 52-Week Study of Dose Adjusted Subcutaneous Testosterone Enanthate in Oil Self-Administered via Disposable Auto-Injector. J Urol 2019; 201:587.</a></li><li><a class="nounderline abstract_t">Bernstein MS, Hunter RL, Yachnin S. Hepatoma and peliosis hepatis developing in a patient with Fanconi's anemia. N Engl J Med 1971; 284:1135.</a></li><li><a class="nounderline abstract_t">Johnson FL, Lerner KG, Siegel M, et al. Association of androgenic-anabolic steroid therapy with development of hepatocellular carcinoma. Lancet 1972; 2:1273.</a></li><li><a class="nounderline abstract_t">Henderson JT, Richmond J, Sumerling MD. Androgenic-anabolic steroid therapy and hepatocellular carcinoma. Lancet 1973; 1:934.</a></li><li><a class="nounderline abstract_t">Westaby D, Ogle SJ, Paradinas FJ, et al. Liver damage from long-term methyltestosterone. Lancet 1977; 2:262.</a></li><li><a class="nounderline abstract_t">Overly WL, Dankoff JA, Wang BK, Singh UD. Androgens and hepatocellular carcinoma in an athlete. Ann Intern Med 1984; 100:158.</a></li><li class="breakAll">https://www.fda.gov/news-events/press-announcements/fda-approves-new-oral-testosterone-capsule-treatment-men-certain-forms-hypogonadism.</li><li class="breakAll">Highlights of prescribing information: Kyzatrex. Food and Drug Administration. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213953s000lbl.pdf (Accessed on August 31, 2022).</li><li><a class="nounderline abstract_t">Seftel A. Testosterone replacement therapy for male hypogonadism: part III. Pharmacologic and clinical profiles, monitoring, safety issues, and potential future agents. Int J Impot Res 2007; 19:2.</a></li><li class="breakAll">http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails (Accessed on June 03, 2014).</li><li><a class="nounderline abstract_t">Page ST, Kalhorn TF, Bremner WJ, et al. Intratesticular androgens and spermatogenesis during severe gonadotropin suppression induced by male hormonal contraceptive treatment. J Androl 2007; 28:734.</a></li><li><a class="nounderline abstract_t">Liu PY, Swerdloff RS, Anawalt BD, et al. Determinants of the rate and extent of spermatogenic suppression during hormonal male contraception: an integrated analysis. J Clin Endocrinol Metab 2008; 93:1774.</a></li><li><a class="nounderline abstract_t">Behre HM, Zitzmann M, Anderson RA, et al. Efficacy and Safety of an Injectable Combination Hormonal Contraceptive for Men. J Clin Endocrinol Metab 2016; 101:4779.</a></li><li><a class="nounderline abstract_t">Khera M, Grober ED, Najari B, et al. Testosterone replacement therapy following radical prostatectomy. J Sex Med 2009; 6:1165.</a></li><li><a class="nounderline abstract_t">Bolognese JA, Kozloff RC, Kunitz SC, et al. Validation of a symptoms questionnaire for benign prostatic hyperplasia. Prostate 1992; 21:247.</a></li><li><a class="nounderline abstract_t">Drach GW, Layton T, Bottaccini MR. A method of adjustment of male peak urinary flow rate for varying age and volume voided. J Urol 1982; 128:960.</a></li><li><a class="nounderline abstract_t">Bruskewitz RC, Iversen P, Madsen PO. Value of postvoid residual urine determination in evaluation of prostatism. Urology 1982; 20:602.</a></li><li><a class="nounderline abstract_t">Basaria S. Male hypogonadism. Lancet 2014; 383:1250.</a></li><li><a class="nounderline abstract_t">Swerdloff RS, Pak Y, Wang C, et al. Serum Testosterone (T) Level Variability in T Gel-Treated Older Hypogonadal Men: Treatment Monitoring Implications. J Clin Endocrinol Metab 2015; 100:3280.</a></li><li><a class="nounderline abstract_t">Muram D, Zhang X, Cui Z, Matsumoto AM. Use of Hormone Testing for the Diagnosis and Evaluation of Male Hypogonadism and Monitoring of Testosterone Therapy: Application of Hormone Testing Guideline Recommendations in Clinical Practice. J Sex Med 2015; 12:1886.</a></li><li><a class="nounderline abstract_t">Gerstenbluth RE, Maniam PN, Corty EW, Seftel AD. Prostate-specific antigen changes in hypogonadal men treated with testosterone replacement. J Androl 2002; 23:922.</a></li><li><a class="nounderline abstract_t">Meikle AW, Arver S, Dobs AS, et al. Prostate size in hypogonadal men treated with a nonscrotal permeation-enhanced testosterone transdermal system. Urology 1997; 49:191.</a></li><li><a class="nounderline abstract_t">Curran MJ, Bihrle W 3rd. Dramatic rise in prostate-specific antigen after androgen replacement in a hypogonadal man with occult adenocarcinoma of the prostate. Urology 1999; 53:423.</a></li><li><a class="nounderline abstract_t">Behre HM, Bohmeyer J, Nieschlag E. Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls. Clin Endocrinol (Oxf) 1994; 40:341.</a></li><li><a class="nounderline abstract_t">Michaud JE, Billups KL, Partin AW. Testosterone and prostate cancer: an evidence-based review of pathogenesis and oncologic risk. Ther Adv Urol 2015; 7:378.</a></li><li><a class="nounderline abstract_t">Boyle P, Koechlin A, Bota M, et al. Endogenous and exogenous testosterone and the risk of prostate cancer and increased prostate-specific antigen (PSA) level: a meta-analysis. BJU Int 2016; 118:731.</a></li><li><a class="nounderline abstract_t">Wilson JD. The pathogenesis of benign prostatic hyperplasia. Am J Med 1980; 68:745.</a></li><li><a class="nounderline abstract_t">Ponce OJ, Spencer-Bonilla G, Alvarez-Villalobos N, et al. The efficacy and adverse events of testosterone replacement therapy in hypogonadal men: A systematic review and meta-analysis of randomized, placebo-controlled trials. J Clin Endocrinol Metab 2018.</a></li><li><a class="nounderline abstract_t">Fernández-Balsells MM, Murad MH, Lane M, et al. Clinical review 1: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2010; 95:2560.</a></li><li><a class="nounderline abstract_t">Calof OM, Singh AB, Lee ML, et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci 2005; 60:1451.</a></li><li><a class="nounderline abstract_t">Braekkan SK, Mathiesen EB, Njølstad I, et al. Hematocrit and risk of venous thromboembolism in a general population. The Tromso study. Haematologica 2010; 95:270.</a></li><li><a class="nounderline abstract_t">Glueck CJ, Wang P. Testosterone therapy, thrombosis, thrombophilia, cardiovascular events. Metabolism 2014; 63:989.</a></li><li class="breakAll">https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-cautions-about-using-testosterone-products-low-testosterone-due (Accessed on January 06, 2020).</li><li class="breakAll">Endocrine Society. Endocrine Society Calls for Large-Scale Studies to Evaluate Testosterone Therapy Risks. https://www.endocrine.org/news-room/press-release-archives/2014/endocrine-society-calls-for-large-scale-studies-to-evaluate-testosterone-therapy-risks (Accessed on January 23, 2015).</li><li class="breakAll">http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm436280.htm (Accessed on April 14, 2015).</li><li><a class="nounderline abstract_t">Shores MM, Smith NL, Forsberg CW, et al. Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab 2012; 97:2050.</a></li><li><a class="nounderline abstract_t">Srinivas-Shankar U, Roberts SA, Connolly MJ, et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 2010; 95:639.</a></li><li><a class="nounderline abstract_t">Basaria S, Harman SM, Travison TG, et al. Effects of Testosterone Administration for 3 Years on Subclinical Atherosclerosis Progression in Older Men With Low or Low-Normal Testosterone Levels: A Randomized Clinical Trial. JAMA 2015; 314:570.</a></li><li><a class="nounderline abstract_t">Baillargeon J, Urban RJ, Kuo YF, et al. Risk of Myocardial Infarction in Older Men Receiving Testosterone Therapy. Ann Pharmacother 2014; 48:1138.</a></li><li><a class="nounderline abstract_t">Sharma R, Oni OA, Gupta K, et al. Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men. Eur Heart J 2015; 36:2706.</a></li><li><a class="nounderline abstract_t">Xu L, Freeman G, Cowling BJ, Schooling CM. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med 2013; 11:108.</a></li><li><a class="nounderline abstract_t">Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med 2010; 363:109.</a></li><li><a class="nounderline abstract_t">Budoff MJ, Ellenberg SS, Lewis CE, et al. Testosterone Treatment and Coronary Artery Plaque Volume in Older Men With Low Testosterone. JAMA 2017; 317:708.</a></li><li><a class="nounderline abstract_t">Vigen R, O'Donnell CI, Barón AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA 2013; 310:1829.</a></li><li><a class="nounderline abstract_t">Finkle WD, Greenland S, Ridgeway GK, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One 2014; 9:e85805.</a></li><li><a class="nounderline abstract_t">Layton JB, Meier CR, Sharpless JL, et al. Comparative Safety of Testosterone Dosage Forms. JAMA Intern Med 2015; 175:1187.</a></li><li><a class="nounderline abstract_t">Wilson DE, Kaidbey K, Boike SC, Jorkasky DK. Use of topical corticosteroid pretreatment to reduce the incidence and severity of skin reactions associated with testosterone transdermal therapy. Clin Ther 1998; 20:299.</a></li><li><a class="nounderline abstract_t">Rolf C, Knie U, Lemmnitz G, Nieschlag E. Interpersonal testosterone transfer after topical application of a newly developed testosterone gel preparation. Clin Endocrinol (Oxf) 2002; 56:637.</a></li><li><a class="nounderline abstract_t">Bhowmick SK, Ricke T, Rettig KR. Sexual precocity in a 16-month-old boy induced by indirect topical exposure to testosterone. Clin Pediatr (Phila) 2007; 46:540.</a></li><li class="breakAll">US Food and Drug Administration. FDA News Release, May 7, 2009. Testosterone gel safety concerns prompt FDA to require label changes, medication guide. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2009/ucm149580.htm (Accessed on September 23, 2011).</li></ol></div><div id="topicVersionRevision">Topic 7461 Version 50.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24024838" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Gonadal steroids and body composition, strength, and sexual function in men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29562364" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9024227" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Testosterone replacement increases fat-free mass and muscle size in hypogonadal men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9253305" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Long-term effect of testosterone therapy on bone mineral density in hypogonadal men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19225035" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Comparison of long-acting testosterone undecanoate formulation versus testosterone enanthate on sexual function and mood in hypogonadal men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15562020" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11701431" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Testosterone dose-response relationships in healthy young men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17609296" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Exogenous testosterone alone or with finasteride does not improve measurements of cognition in healthy older men with low serum testosterone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10946864" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Effects of testosterone replacement in hypogonadal men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22804876" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Abrupt decrease in serum testosterone levels after an oral glucose load in men: implications for screening for hypogonadism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26886521" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Effects of Testosterone Treatment in Older Men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26504097" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Diagnosis and management of testosterone deficiency syndrome in men: clinical practice guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23939517" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Trends in androgen prescribing in the United States, 2001 to 2011.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23939515" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Promoting "low T": a medical writer's perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23939516" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Low "T" as in "template": how to sell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24138381" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Global trends in testosterone prescribing, 2000-2011: expanding the spectrum of prescription drug misuse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28324090" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Association Between Direct-to-Consumer Advertising and Testosterone Testing and Initiation in the United States, 2009-2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10720024" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a General Clinical Research Center Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10859732" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Androgel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11134099" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21454244" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Pharmacokinetics and relative bioavailability of absorbed testosterone after administration of a 1.62% testosterone gel to different application sites in men with hypogonadism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21492400" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Efficacy and safety study of 1.62% testosterone gel for the treatment of hypogonadal men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12614254" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21502933" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : A new testosterone gel (fortesta) for hypogonadism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21979302" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : A novel testosterone 2% gel for the treatment of hypogonadal males.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21689131" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Efficacy and safety of the 2% formulation of testosterone topical solution applied to the axillae in androgen-deficient men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1740497" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8626843" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Pharmacokinetics and metabolism of a permeation-enhanced testosterone transdermal system in hypogonadal men: influence of application site- -a clinical research center study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8877678" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Pharmacokinetics of testosterone in hypogonadal men after transdermal delivery: influence of dose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10522982" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20525905" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10229906" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3782423" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Pharmacokinetic properties of testosterone propionate in normal men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6777395" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Treatment of male hypogonadism with testosterone enanthate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6777395" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Treatment of male hypogonadism with testosterone enanthate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6777395" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Treatment of male hypogonadism with testosterone enanthate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15531493" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15531493" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30296416" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : A 52-Week Study of Dose Adjusted Subcutaneous Testosterone Enanthate in Oil Self-Administered via Disposable Auto-Injector.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4324228" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Hepatoma and peliosis hepatis developing in a patient with Fanconi's anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4117807" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Association of androgenic-anabolic steroid therapy with development of hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4123858" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Androgenic-anabolic steroid therapy and hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/69876" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Liver damage from long-term methyltestosterone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6318626" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Androgens and hepatocellular carcinoma in an athlete.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6318626" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Androgens and hepatocellular carcinoma in an athlete.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6318626" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Androgens and hepatocellular carcinoma in an athlete.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16193074" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Testosterone replacement therapy for male hypogonadism: part III. Pharmacologic and clinical profiles, monitoring, safety issues, and potential future agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16193074" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Testosterone replacement therapy for male hypogonadism: part III. Pharmacologic and clinical profiles, monitoring, safety issues, and potential future agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17494097" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Intratesticular androgens and spermatogenesis during severe gonadotropin suppression induced by male hormonal contraceptive treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18303073" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Determinants of the rate and extent of spermatogenic suppression during hormonal male contraception: an integrated analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27788052" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Efficacy and Safety of an Injectable Combination Hormonal Contraceptive for Men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19207277" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Testosterone replacement therapy following radical prostatectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1279647" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Validation of a symptoms questionnaire for benign prostatic hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6184492" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : A method of adjustment of male peak urinary flow rate for varying age and volume voided.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7179626" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Value of postvoid residual urine determination in evaluation of prostatism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24119423" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Male hypogonadism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26120790" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Serum Testosterone (T) Level Variability in T Gel-Treated Older Hypogonadal Men: Treatment Monitoring Implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26272690" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Use of Hormone Testing for the Diagnosis and Evaluation of Male Hypogonadism and Monitoring of Testosterone Therapy: Application of Hormone Testing Guideline Recommendations in Clinical Practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12399540" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Prostate-specific antigen changes in hypogonadal men treated with testosterone replacement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9037280" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Prostate size in hypogonadal men treated with a nonscrotal permeation-enhanced testosterone transdermal system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9933071" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Dramatic rise in prostate-specific antigen after androgen replacement in a hypogonadal man with occult adenocarcinoma of the prostate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7514512" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26622322" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Testosterone and prostate cancer: an evidence-based review of pathogenesis and oncologic risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26779889" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Endogenous and exogenous testosterone and the risk of prostate cancer and increased prostate-specific antigen (PSA) level: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6155068" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : The pathogenesis of benign prostatic hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29562341" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : The efficacy and adverse events of testosterone replacement therapy in hypogonadal men: A systematic review and meta-analysis of randomized, placebo-controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20525906" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Clinical review 1: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16339333" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19833630" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Hematocrit and risk of venous thromboembolism in a general population. The Tromso study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24930993" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Testosterone therapy, thrombosis, thrombophilia, cardiovascular events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24930993" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Testosterone therapy, thrombosis, thrombophilia, cardiovascular events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24930993" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Testosterone therapy, thrombosis, thrombophilia, cardiovascular events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24930993" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Testosterone therapy, thrombosis, thrombophilia, cardiovascular events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22496507" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Testosterone treatment and mortality in men with low testosterone levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20061435" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26262795" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Effects of Testosterone Administration for 3 Years on Subclinical Atherosclerosis Progression in Older Men With Low or Low-Normal Testosterone Levels: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24989174" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Risk of Myocardial Infarction in Older Men Receiving Testosterone Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26248567" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23597181" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20592293" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Adverse events associated with testosterone administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28241355" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Testosterone Treatment and Coronary Artery Plaque Volume in Older Men With Low Testosterone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24193080" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24489673" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25962056" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Comparative Safety of Testosterone Dosage Forms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9589821" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Use of topical corticosteroid pretreatment to reduce the incidence and severity of skin reactions associated with testosterone transdermal therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12030915" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Interpersonal testosterone transfer after topical application of a newly developed testosterone gel preparation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17579107" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Sexual precocity in a 16-month-old boy induced by indirect topical exposure to testosterone.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
